Lucy Penfold
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Correction: The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer.
Journal: British journal of cancer
Published: February 14, 2024
The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer.
Journal: British journal of cancer
Published: July 20, 2022
AMPK activation protects against prostate cancer by inducing a catabolic cellular state.
Journal: Cell reports
Published: May 31, 2022
Chronic activation of AMP-activated protein kinase leads to early-onset polycystic kidney phenotype.
Chronic activation of AMP-activated protein kinase leads to early-onset polycystic kidney phenotype.
Journal: Clinical science (London, England : 1979)
Published: August 19, 2021
Systems level profiling of chemotherapy-induced stress resolution in cancer cells reveals druggable trade-offs.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: April 22, 2021
AMPK activation protects against diet induced obesity through Ucp1-independent thermogenesis in subcutaneous white adipose tissue.
Journal: Nature metabolism
Published: March 20, 2019
CAMKK2 Promotes Prostate Cancer Independently of AMPK via Increased Lipogenesis.
Journal: Cancer research
Published: February 22, 2018
Showing 1-8 of 8
Last Updated: 09/26/2026